Amgen's biosimilar Humira meets in RA equivalence trial

Amgen Inc. (NASDAQ:AMGN) said its ABP 501 met the primary endpoint of equivalence, as measured by ACR20 at week 24, to Humira adalimumab from AbbVie

Read the full 251 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE